Generalized Anxiety Disorder (GAD) MedDRA version: 9.1 Level: LLT Classification code 10018105 Term: Generalized anxiety disorder
Conditions
Sponsors
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of GAD (Diagnostic and Statistical Manual-IV [DSM-IV], 300.02) as established by the clinician (psychiatrist or licensed clinical psychologist) who has interviewed the subject using all sources of data including the Mini International Neuropsychiatric Interview (MINI) for DSM-IV Axis I disorders and other clinical information. Subjects with specific phobia(s) (as defined in DSM-IV) or dysthymic disorder will be allowed in the study. 2. Subjects must have a HAM-A total score =20 at the screening (V1) and randomization (V2) visits. Subjects must also have a Covi Anxiety Scale score of =9 and a Raskin Depression Scale score =7 at the Screening (V1) visit to ensure predominance of anxiety symptoms over depression symptoms. 3. Otherwise healthy men or non-pregnant, non-lactating women (women must be using a hormonal or barrier method of contraception or be postmenopausal or surgically sterilized). Healthy is defined as no other clinically relevant abnormalities identified by a detailed medical history, full physical examination including sitting blood pressure (BP) and heart rate measurement, 12-lead ECG, and clinical laboratory tests. 4. Age 18 to 65 years, inclusive. 5. All women must have negative pregnancy tests at the Screening (V1) and Randomization (V2) visits. 6. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. 7. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, neurologic, active infections, immunological, or allergic disease (including drug allergies). 2. Any of the following current (within the past 6 months through the present) DSM-IV Axis I diagnoses: Major depressive disorder; Obsessive compulsive disorder; Panic disorder; Agoraphobia; Posttraumatic stress disorder; Anorexia; Bulimia; Caffeine-induced anxiety disorder; Alcohol or substance abuse or dependence unless in full remission for at least 6 months; Social anxiety disorder. 3. Any of the following past or current DSM-IV Axis I diagnoses: Schizophrenia; Psychotic disorder; Delirium, dementia, amnestic, and other clinically significant cognitive disorders; Bipolar or schizoaffective disorder; Cyclothymic disorder; Dissociative disorders. 4. Antisocial or borderline personality disorder. 5. Serious suicidal risk per the clinical investigator’s judgment. (Note: The Suicidality module of the MINI diagnostic interview and the C-SSRS should be used as aids to the assessment of suicidality, but do not replace overall clinical judgment in determination of suicidal risk). 6. Current use of psychotropic medications (ie, drugs normally prescribed for depression, mania, anxiety, insomnia, or psychosis) that cannot be discontinued 2 weeks prior to randomization. Fluoxetine is prohibited within 5 weeks of randomization. In the event of inadvertent administration of psychotropic medications during the 2 weeks prior to randomization, continued eligibility will be assessed on a case by case basis by the investigator and the medical monitor. 7. Use of drugs, supplements, prescription or nonprescription, or food that have psychoactive properties. In the event of inadvertent use of such products during the 2 weeks prior to randomization, continued eligibility will be assessed on a case by case basis by the investigator and the medical monitor. In addition, following a discussion of the individual case between the medical monitor and the investigator, the medical monitor may allow minimal anxiolytic medication (for example a benzodiazepine) use for subjects who experience significant intolerable anxiety during the final week of the study (Days 64-71). 8. Subjects who have been treated with monoamine oxidase inhibitors in the 14 days prior to the baseline visit. 9. Regular use of benzodiazepines during the 3 months prior to Screening (for at least 5 out of 7 days per week). 10. Subjects initiating formal psychotherapy within 3 month prior to screening who intend to continue formal psychotherapy during the study. This includes psychodynamic, cognitive, and interpersonal therapies. 11. Positive drug tests at Screening (V1) or Randomization (V2) visits for any of the following substances or classes of compounds: amphetamines, barbiturates, opiates, benzodiazepines, sedatives and hypnotics, cocaine, phencyclidine (PCP), cannabinoids, or other illegal or illicit drugs. An exception to the exclusion for a positive benzodiazepine, opiate, or sedative and hypnotic drug test at the Screening (V1) visit may be granted by the Pfizer medical monitor if written evidence of a valid, current prescription is presented. 12. Any condition possibly affecting drug absorption (eg, gastrectomy). 13. Subjects with a current seizure disorder. 14. Subjects with a history of life-threatening neoplasms within 5 years pr
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: • To assess the efficacy of PD 0332334 in the treatment of GAD as measured by the change from Baseline in the HAM-A total score at Week 8. • To assess the safety and tolerability of PD 0332334 in subjects with GAD.;Secondary Objective: • To assess the effects of PD 0332334 on disability (as measured by the change from baseline at Week 8 in the Sheehan Disability total score) associated with GAD. • To assess the time course of action of PD 0332334 on the symptoms of GAD (as measured by the change from baseline HAM-A) over the 8-week double-blind treatment period. • To assess the effect of PD 0332334 on the somatic symptoms of GAD. • To assess the effect of PD 0332334 on the psychic symptoms of GAD. • To assess the effect of PD 0332334 on the patient reported symptom of GAD. • To assess the Week 1 sustained response (based on the HAM-A total score) with PD 0332334 in the treatment of GAD. • To assess the effects of PD 0332334 on sleep problems in subjects with GAD. • To assess the effect of PD 0332334 on depressive symptoms in subjects with GAD. • To assess the efficacy of PD 0332334 in the treatment of GAD as assessed by clinical and patient global impressions.;Primary end point(s): Change from Baseline in HAM-A total score at Week 8. | — |
Countries
Germany, Hungary, Italy
Outcome results
None listed